Stockscreener 앱 받기
18.04
11.50%
1.86
전일 마감가:
$16.18
열려 있는:
$16.13
하루 거래량:
778.49K
Relative Volume:
1.31
시가총액:
$988.27M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+22.06%
1개월 성능:
+5.74%
6개월 성능:
+23.65%
1년 성능:
+1.52%
1일 변동 폭
$15.83
$18.16
1주일 범위
$14.62
$18.16
52주 변동 폭
$7.80
$22.68
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.04 | 886.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $29.67 Average Price Target from Analysts - Defense World
Analyzing Bicara Therapeutics Inc. with risk reward ratio chartsTrade Volume Report & High Conviction Buy Zone Picks - newser.com
Taking the lead: Bicara Therapeutics Inc (BCAX) - Setenews
How currency fluctuations impact Bicara Therapeutics Inc. stock2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
How to manage a losing position in Bicara Therapeutics Inc.Market Activity Summary & Fast Gain Swing Alerts - newser.com
How institutional buying supports Bicara Therapeutics Inc. stock2025 Geopolitical Influence & Capital Protection Trading Alerts - newser.com
Is Bicara Therapeutics Inc. stock resilient to inflationQuarterly Earnings Summary & Daily Technical Forecast Reports - newser.com
What institutional flow reveals about Bicara Therapeutics Inc.Weekly Market Report & Weekly High Conviction Trade Ideas - newser.com
Will a bounce in Bicara Therapeutics Inc. offer an exitTreasury Yields & AI Powered Market Entry Strategies - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Wedbush Has Bearish Estimate for BCAX FY2025 Earnings - Defense World
How Bicara Therapeutics Inc. stock benefits from global expansion2025 Earnings Impact & Community Verified Swing Trade Signals - newser.com
Real time alert setup for Bicara Therapeutics Inc. performance2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Wells Fargo Maintains Bicara Therapeutics (BCAX) Equal-Weight Recommendation - Nasdaq
An analyst sees good growth prospects for Bicara Therapeutics Inc (BCAX) - Setenews
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):